


# Factors Influencing Chronic Hepatitis C Treatment Results



Due to its distribution and clinical course, chronic viral hepatitis C has become one of the most common infectious diseases in the world. At present the number of the infected in the world is about 170 million, but in Europe it exceeds 9 million. The incidence of chronic viral hepatitis C in Latvia is relatively high. The antibody prevalence is 2.4%, HCV-RNA prevalence is 1.7%, it means that in Latvia there might be almost 40 000 chronic hepatitis C patients. This study gives an opportunity to calculate positive treatment result possibility for every chronic viral hepatitis C patient.

chronic hepatitis C. However, poor patient adherence to therapy negatively influences drug levels. Results of a head-to-head comparison have demonstrated. Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease. Factors affecting the efficacy of anti-HCV treatments based on IFN- $\alpha$  include the HCV genotype, the duration of infection, and the presence of cirrhosis. The results showed that the curative effects of the two treatments were similar. Buy Factors Influencing Chronic Hepatitis C Treatment Results at . Characteristics of the patients with chronic hepatitis C and studied variables. All two cases with genotype 2 were treated successfully. Chronic hepatitis C (CHC) affects over 170 million people worldwide and is a leading cause of liver disease. Similar findings were subsequently reported by others in mice treated with the CB1 . D. Dhumeaux. Epidemiological factors affecting the severity of hepatitis C. Factors influencing adherence in Hepatitis-C infected patients: a systematic review. Tim Mathes. Email author, Sunya-Lee Antoine and Dawid Pieper. Trop Doct. 2016 Jan;46(1):28-33. doi: 10.1177/0049475515569519. Epub 2015 Feb 1. Factors affecting outcome of treatment of chronic hepatitis C: result of a head-to-head comparison. Most of the disease burden associated with HCV infection results from the .. the magnitude of the relative influence of individual factors on treatment success. Liver biopsy demonstrating a recurrence of chronic hepatitis-C. Treated with ribavirin plus peg-interferon. The results of the individual analyses for each influencing factor are presented in Table 3. treatment for Hepatitis C was a combination of ribavirin and interferon. This report is intended . 3.2 User profile-related factors influencing HCV treatment .. 16. 3.2.1 Clinical factors, comorbidities and side-effects . The Hepatitis C virus (HCV) is a blood-borne virus and a leading cause of chronic liver disease. These results may have been affected by HIV-1 coinfection, HCV reinfection, the .. risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a .. and ribavirin for treatment of chronic hepatitis C (CHC) are well recognized, and . RESULTS: CHC patients (303) were assessed for antiviral therapy from Standard treatment for HCV infection is a combination of long-lasting interferon and the nucleoside analog ribavirin. However, because of side effects these drugs can be poorly tolerated. Gender influence on treatment of chronic hepatitis C genotype 1 . RESULTS: Among 181 patients undergoing treatment, the mean age was 46.4  $\pm$  11.0 . Parenteral risk factor for HCV acquisition was defined as history of blood transfusion (if any). Factors influencing the response to interferon therapy in chronic hepatitis C. The induction of 25-OH vitamin D was correlated to the results of IFN- $\alpha$  treatment in 36 patients. Methods: Fifty-two chronic hepatitis C patients (Child class A) were treated with interferon- $\alpha$  and ribavirin. Conclusion: Treatment outcome and factors affecting it are similar to studies from Europe. Factors Influencing Statin use in Patients Medically Managed for Chronic Hepatitis C Virus (HCV) in an Urban Healthcare System\* . Patients treated for HCV may not be appropriately managed with statins

based on loss to follow up after DAA completion and limited access to pre-statin lipid panel results.